Sofosbuvir and ribavirin in acute hepatitis C–infected patient with decompensated cirrhosis. Issue 49 (December 2016)

• Record Type: Journal Article
• Authors: Liu, Hui; Zhang, Tong; Yan, Yan
• Other Names: Lin. Wenyu section editor.
• Is Part Of: Medicine. Volume 95:Issue 49(2016)
• Publication Date: 2016-12
• Subjects: case report -- decompensated cirrhosis -- HCV -- hepatitis -- ribavirin -- sofosbuvir; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000005555
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract: Background: The treatment of chronic hepatitis C virus infection has been revolutionized by the advent of direct-acting antiviral agents. However, evidence of its effects on patients with acute hepatitis C (AHC) virus infection is limited. Case summary: We report the case of a patient with decompensated cirrhosis induced by autoimmune liver disease, whose condition rapidly deteriorated following AHC virus infection. The patient received sofosbuvir and ribavirin combination treatment for 12 weeks. Serum hepatitis C virus RNA remained undetectable 36 weeks after discontinuing sofosbuvir and ribavirin. Conclusion: Our findings support the use of sofosbuvir and ribavirin as a treatment in AHC patients with decompensated cirrhosis.